Note the part about "adding $2 billion in yearly revenues" from just this one indication.
While pertuzumab binds to a cell receptor and is thus working in a different arena than Lpath's (current) mAbs, the advance underlines how targeted these therapies can be and how effective. Monoclonal antibodies, which can be exquisitely engineered to go after specific chemical targets, are indeed proving to be "game changers" in treating difficult diseases. The health benefits can be great and the markets are enormous. It's a hot area in biotech if you have an innovative discovery platform. I like where we are.
I noticed an announcement today concerning the Swedish firm, Dako, who will be collaborating with Genentech in developing diagnostic testing for Pertuzamab.
Diagnostic testing is a must have for firms looking to commercialize their drug candidates if they want to have the "total package", thus maximizing its value to the medical community and to the company.
Do you know if LPath has plans to develop its own diagnostics?
I am heavily invested in several companies developing monoclonal antibodies and immunotherapy treatments. I try to key on trial results and compare efficacy rates and what market potential is for their applications. LPTN definitely has a bright future.